Boothbay Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boothbay Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-132	Closed	-$1.57M	–	1348
2020 Q3	$1.57M	Buy	132 +76	+136%	+$8.25K	0.09%	288
2020 Q2	$634K	Buy	+56	New	+$5.51K	0.04%	518
2019 Q3	–	Sell	-287	Closed	-$3.01M	–	851
2019 Q2	$3.01M	Sell	287 -177	-38%	-$19K	0.27%	87
2019 Q1	$5.81M	Sell	464 -212	-31%	-$26.4K	0.56%	28
2018 Q4	$7.62M	Buy	676 +474	+235%	+$73.4K	1.11%	15
2018 Q3	$4.33M	Buy	202 +75	+59%	+$18.8K	0.43%	51
2018 Q2	$3.55M	Buy	+127	New	+$22.3K	0.31%	63

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's MDGL Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 1,857 shares worth $997K. The stake represents 0.01% of the portfolio and ranks #1092 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in MDGL as recently as Q3 2025.

Boothbay Fund Management first reported a position in MDGL in Q1 2019 and has held it in 13 quarters since. The position peaked at $2.18M in Q2 2020. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Boothbay Fund Management held 1,857 shares of Madrigal Pharmaceuticals worth $997K as of Q2 2026.
Madrigal Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
Madrigal Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1092 holding.
Boothbay Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
Boothbay Fund Management's Madrigal Pharmaceuticals position peaked at $2.18M in Q2 2020.
415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.